Meropenem Monotherapy as an Empirical Treatment of Febrile Neutropenia in Childhood Cancer Patients

被引:0
作者
Erbey, Fatih [1 ]
Bayram, Ibrahim
Yilmaz, Sema
Tanyeli, Atila
机构
[1] Cukurova Univ, Fac Med, Dept Pediat Oncol, TR-01330 Adana, Turkey
关键词
Choldhood cancer; febrile neutropenia; meropenem treatment; PLUS AMIKACIN; SOLID TUMORS; RISK-FACTORS; CHILDREN; CEFEPIME; FEVER; CEFTAZIDIME; INFECTION;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Chemotherapy related neutropenia developing in oncologic patients is a significant condition and major cause of morbidity and mortality. Febrile neutropenic attacks without complications can be successfully treated with wide-spectrum anti-pseudomonal cephalosporins or carbapenems. Objective: We investigated the efficacy and safety of meropenem in the treatment of febrile neutropenia (FN) in children with cancer. Materials and Methods: Twenty four patients who had a febrile neutropenic episodes followed by initiation of empirical meropenem therapy were included in the study. Results: Of all the patients, 13 (54.2%) had solid tumors, while 11 (45.8%) were diagnosed to have acute leukemia. Among all, 7 (29.2%) and 15 (62.5%) infections were identified microbiologically and clinically, respectively. Fever of unknown origin was observed in 2 (8.3%) patients. The mean duration of neutropenia was 7.2 +/- 3.1 (4-14) days in patients with solid tumors, and 9.3 +/- 4.7 (2-17) days in the group with leukemia. This difference was not statistically significant (log rank, p=0.063). Average time of stay in hospital was 10.1 +/- 6.4 (4-21) days for patients with solid tumors, and 15.9 +/- 11.7 (5-37) days for patients with leukemia (log rank, p=0.041). FN duration was observed to be significantly longer in patients with an absolute neutrophil count (ANC) of less than 100/mm(3) and even those with an ANC of less than 200/mm(3), and in children who were not in remission for the underlying malign disease (p<0.05). While 22 (91.7%) of the patients were discharged from the hospital, 2 (8.3%) died. The success rate of empirical therapy started with meropenem was 87.5%. Conclusion: Meropenem is effective and safe for treatment of FN in pediatric cancer patients.
引用
收藏
页码:123 / 126
页数:4
相关论文
共 14 条
[1]   Cost-effectiveness of cefepime plus netilmicin or ceftazidime plus amikacin or meropenem monotherapy in febrile neutropenic children with malignancy in Turkey [J].
Agaoglu, L ;
Devecioglu, O ;
Anak, S ;
Karakas, Z ;
Yalman, N ;
Biner, B ;
Eryilmaz, E ;
Goksan, B ;
Unuvar, A ;
Agirbasli, H ;
Can, M ;
Bilgen, H ;
Gedikoglu, G .
JOURNAL OF CHEMOTHERAPY, 2001, 13 (03) :281-287
[2]   Meropenem - A review of its use in the treatment of serious bacterial infections [J].
Baldwin, Claudine M. ;
Lyseng-Williamson, Katherine A. ;
Keam, Susan J. .
DRUGS, 2008, 68 (06) :803-838
[3]  
Erbey F, 2009, ASIAN PAC J CANCER P, V10, P921
[4]   A comparison of outcome from febrile neutropenic episodes in children compared with adults: results from four EORTC studies [J].
Hann, I ;
Viscoli, C ;
Paesmans, M ;
Gaya, H ;
Glauser, M .
BRITISH JOURNAL OF HAEMATOLOGY, 1997, 99 (03) :580-588
[5]   2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer [J].
Hughes, WT ;
Armstrong, D ;
Bodey, GP ;
Bow, EJ ;
Brown, AE ;
Calandra, T ;
Feld, R ;
Pizzo, PA ;
Rolston, KVI ;
Shenep, JL ;
Young, LS .
CLINICAL INFECTIOUS DISEASES, 2002, 34 (06) :730-751
[6]   Infection risk factors in febrile, neutropenic children and adolescents [J].
Jones, GR ;
Konsler, GK ;
Dunaway, RP ;
Pusek, SN .
PEDIATRIC HEMATOLOGY AND ONCOLOGY, 1996, 13 (03) :217-229
[7]   Cefepime vs. meropenem as empirical therapy for neutropenic fever in children with lymphoma and solid tumours [J].
Kutluk, T ;
Kurne, O ;
Akyüz, C ;
Ceyhan, M ;
Kanra, G ;
Büyükpamukçu, M ;
Seçmeer, G .
PEDIATRIC BLOOD & CANCER, 2004, 42 (03) :284-286
[8]   Meropenem in the treatment of febrile neutropenic children [J].
Müller, J ;
Garami, M ;
Constantin, T ;
Schmidt, M ;
Fekete, G ;
Kovács, G .
PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2005, 22 (04) :277-284
[9]   Experience with cefepime versus meropenem as empiric monotherapy for neutropenia and fever in pediatric patients with solid tumors [J].
Oguz, A ;
Karadeniz, C ;
Citak, EC ;
Cil, V ;
Eldes, N .
PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2006, 23 (03) :245-253
[10]   Febrile Neutropenia in Children with Cancer [J].
Paulus, Stephane ;
Dobson, Simon .
HOT TOPICS IN INFECTION AND IMMUNITY IN CHILDREN V, 2009, 634 :185-204